MARKET

TNDM

TNDM

Tandem Diabetes
NASDAQ

Real-time Quotes | Nasdaq Last Sale

104.95
-1.45
-1.36%
Opening 15:17 09/21 EDT
OPEN
104.69
PREV CLOSE
106.40
HIGH
105.12
LOW
102.41
VOLUME
423.08K
TURNOVER
--
52 WEEK HIGH
116.89
52 WEEK LOW
43.69
MARKET CAP
6.39B
P/E (TTM)
-149.5014
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
DexCom: A Superior Business Model But Watch Out For Debt Level
DexCom produces continuous glucose monitoring devices.The stock price has increased steeply in the last one year, but a slight dip recently constitutes an opportunity for investors.The medical devices company has enjoyed double-digit growth and looks likely to continue when considering the business model.It has a high level of product differentiation compared with competitors but debt level is also higher.The stock has the potential to climb much higher.
Seekingalpha · 1d ago
Hedge Funds Are Buying Tandem Diabetes Care Inc (TNDM) Again
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of June 30th, when the S&P 500 Index
Insider Monkey · 6d ago
The Daily Biotech Pulse: Sanofi, GSK Begin Phase 1/2 Coronavirus Vaccine Study, Fulgent Strikes COVID-19 Testing Deal, New Data From Novavax
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2)
Benzinga · 09/03 11:55
Tandem Diabetes Care Announces Upcoming Webcast Conference Presentations
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that John Sheridan, president and chief executive officer, will present a company update at the following virtual investor conferences:
Business Wire · 09/02 20:05
The Daily Biotech Pulse: Amarin's Vascepa Appeal Hearing, Avid Bioservices' Strong Q1, A Life Sciences Blank Check IPO
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1)
Benzinga · 09/02 11:25
Bullish momentum persists: S&P 500, Nasdaq sustain key technical breakouts
U.S. stocks are higher early Friday, rising after a solid batch of economic data and as markets continue to digest recently dovish Federal Reserve policy...
marketwatch.com · 08/28 16:13
Tandem Diabetes' Advanced Insulin Pump Study Results Favorable
Per the DCLP5 study, Tandem Diabetes' (TNDM) insulin pump with Control-IQ technology suitable for use in children aged six to 13 years, which has been published in the NEJM.
Zacks · 08/28 13:26
The Daily Biotech Pulse: Modrerna Japanese Vaccine Deal Talk, Lipocine FDA Decision, Liver Congress Presentations
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 27)
Benzinga · 08/28 12:26
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 15 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TNDM stock price target is 120.47 with a high estimate of 140.00 and a low estimate of 97.00.
EPS
Institutional Holdings
Institutions: 418
Institutional Holdings: 63.58M
% Owned: 104.39%
Shares Outstanding: 60.91M
TypeInstitutionsShares
Increased
79
4.05M
New
104
1.22M
Decreased
116
6.79M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-1.94%
Healthcare Equipment & Supplies
-2.00%
Key Executives
Chairman/Director
Kim Blickenstaff
President/Chief Executive Officer/Director
John Sheridan
Chief Financial Officer/Executive Vice President/Treasurer
Leigh Vosseller
Executive Vice President/Chief Administrative Officer
Susan Morrison
Executive Vice President/Chief Compliance Officer/Secretary
David Berger
Executive Vice President
Elizabeth Gasser
Executive Vice President
Brian Hansen
Lead Director/Independent Director
Dick Allen
Independent Director
Edward Cahill
Independent Director
Peyton Howell
Independent Director
Kathleen McGroddy-Goetz
Independent Director
Rebecca Robertson
Independent Director
Douglas Roeder
Independent Director
Christopher Twomey
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More

Analyst Price Target

The average TNDM stock price target is 120.47 with a high estimate of 140.00 and a low estimate of 97.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About TNDM
Tandem Diabetes Care, Inc. is a medical device company engaged in the designing, developing and commercialization of products for people with insulin-dependent diabetes. The Company’s manufacturing, sales and support activities principally focus on its flagship pump platform, the t:slim X2 Insulin Delivery System (t:slim X2), and its product offerings. The t:slim X2 is based on its technology platform and is capable of remote feature updates and is designed to display continuous glucose monitoring (CGM) sensor information directly on the pump home screen. Its products also include Basal-IQ technology and Control-IQ technology. The Basal-IQ technology is a predictive low glucose suspend feature that is designed to temporarily suspend insulin delivery to help reduce the frequency and duration of hypoglycemic events. The Control-IQ technology is a hybrid-closed loop feature, designed to help increase a user's time in targeted glycemic range.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Tandem Diabetes Care Inc stock information, including NASDAQ:TNDM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TNDM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TNDM stock methods without spending real money on the virtual paper trading platform.